Authors of a literature review note the high prevalence of liver disease among people with HIV and recommend a step-by-step approach to management.
This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.
Sixteen years after the success of Project START for HIV risk reduction, we still don't know what works best for helping people with HIV stay in care after prison.
Despite rising HIV rates and structural barriers to accessing care, American Indians and Alaska Natives do not have worse clinical outcomes when they're in care.
A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.
Study results of an intervention that includes a custom smartphone app tailored to the needs and preferences of a rural population of people with HIV living in the southern U.S.
"Since this appears to be a 'best in class' drug, doravirine has enough advantages that it is a useful advance in HIV therapy, if not a transformational one," writes Paul Sax, M.D.
On Aug. 30, 2018, the U.S. FDA approved doravirine as a separate formulation for use with ART and in a fixed-dose combination with generic tenofovir DF and lamivudine (3TC).
After 96 weeks, more people achieved viral suppression on a doravirine-based antiretroviral drug regimen compared with a darunavir (Prezista)-based one, according to data presented at the recent 22nd International AIDS Conference.